CDC panel reviews clot risk linked to J&J’s vaccine

A government advisory panel was meeting Thursday to determine if any restrictions are needed for the Johnson & Johnson COVID-19 vaccine because of rare but serious blood clots.

A strange clotting problem prompted the U.S. to temporarily halt the single-dose J&J shots last April while scientists investigated. Eventually regulators decided the benefits of a one-and-done vaccine outweighed what was considered a very rare risk, as long as recipients were warned.

While it is still rare, the Food and Drug Administration told health care providers this week that more cases have occurred since the spring. They occur most in women between 30 and 49, about once for every 100,000 doses administered, the FDA said.

Overall, the government has confirmed 54 clot cases in women and men, and nine deaths that included two men, Dr. Isaac See of the Centers for Disease Control and Prevention said Thursday. He said two additional deaths are suspected.

The CDC decides how vaccines should be used in the U.S., and its influential advisory committee is deliberating whether the newest safety data warrants any new limits on J&J’s vaccine.

More than 200 million Americans are fully vaccinated, about 16 million of them with the J&J vaccine. The other two vaccines used in the U.S., from Pfizer and Moderna, are made differently, and regulators say they don’t come with this clot risk. And unlike in spring when vaccine supplies were tight, Pfizer and Moderna shots now are plentiful in the U.S.

COVID-19 can cause potentially deadly blood clots. But the suspect culprit for the vaccine-related kind is a rogue immune response linked to the J&J shot and a COVID-19 vaccine made by AstraZeneca. Both of those vaccines are made similarly, using a cold virus known as an adenovirus, although AstraZeneca’s shot is not used in the U.S.

The FDA this week warned that another dose of the J&J vaccine shouldn’t be given to anyone who developed a clot following either a J&J or AstraZeneca shot.